论文部分内容阅读
2014年3月19日FDA批准由Paladin公司开发的米替福新(miltefosine)在美国上市,商品名为Impavido。该药为胶囊剂,用于治疗12岁以上患者的内脏利什曼病、皮肤利什曼病和黏膜利什曼病[1]。米替福新的中文化学名称:2-[十六烷氧基(羟基)磷酰氧基]-N,N,N-三甲基乙铵内盐;英文化学名称:2-[hexadecyloxy(hydroxy)phosphoryloxy]-N,N,N-trimethylethanaminium hydroxide inner salt;分子式:C21H46NO4P;分子量:407.57;CAS登记号:58066-85-6。
March 19, 2014 FDA Approves Miltefosine, developed by Paladin Inc., is marketed in the United States under the trade name Impavido. This medicine is a capsule for the treatment of visceral leishmaniasis, cutaneous leishmaniasis and mucosal leishmaniasis in patients over 12 years of age [1]. Miltenfoside New Chinese chemical name: 2- [hexadecyloxy (hydroxy) phosphoryloxy] -N, N, N-trimethylethylammonium salt; English chemical name: 2- [hexadecyloxy ) phosphoryloxy] -N, N, N-trimethylethanaminium hydroxide inner salt; Molecular Formula: C21H46NO4P; Molecular Weight: 407.57; CAS Registry Number: 58066-85-6.